{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T02:12:57Z","timestamp":1774663977539,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.msard.2021.103384","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T06:47:20Z","timestamp":1636354040000},"page":"103384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Relationship between lymphopenia and disease activity in persons with multiple sclerosis treated with dimethyl fumarate"],"prefix":"10.1016","volume":"57","author":[{"given":"Laura","family":"Chu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abedallah","family":"Balusha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney","family":"Casserly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warren","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah A.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.msard.2021.103384_bib0001","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40263-020-00714-8","article-title":"Fingolimod and dimethyl-fumarate-derived lymphopenia is not associated with short-term treatment response and risk of infections in a real-life MS population","volume":"34","author":"Boffa","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2021.103384_bib0002","series-title":"Proceedings of the Poster Presentation, 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis","article-title":"Delayed-release dimethyl fumarate-associated lymphopenia: on-treatment and post-treatment implications","author":"Chan","year":"2018"},{"issue":"5","key":"10.1016\/j.msard.2021.103384_bib0003","first-page":"1","article-title":"Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS","volume":"10","author":"Chan","year":"2020","journal-title":"Neurol. Clin. Pract."},{"issue":"5","key":"10.1016\/j.msard.2021.103384_bib0004","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1177\/1352458517703799","article-title":"Treatment response to dimethyl fumarate is characterized by disproportion CD8+ T cell reduction in MS","volume":"24","author":"Fleischer","year":"2018","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2021.103384_bib0005","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1212\/CPJ.0000000000000238","article-title":"Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: patient management considerations","volume":"6","author":"Fox","year":"2016","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.msard.2021.103384_bib0006","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-activityled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103384_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756286420915005","article-title":"Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years\u2019 follow-up of DEFINE, CONFIRM, and ENDORSE","volume":"13","author":"Gold","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2021.103384_bib0008","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-activityled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103384_bib0009","article-title":"Dimethyl fumarate treatment shifts the immune environment toward and anti-inflammatory cell profile while maintaining protective humoral immunity","author":"Longbrake","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103384_bib0010","article-title":"Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance","volume":"1","author":"Longbrake","year":"2015","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"10","key":"10.1016\/j.msard.2021.103384_bib0011","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3389\/fimmu.2019.01343","article-title":"Lymphocyte count and body mass index as biomarkers of early treatment response in multiple sclerosis dimethyl fumarate-treaetd cohort","volume":"14","author":"Manni","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2021.103384_bib0012","article-title":"Dimethyl fumarate induced lymphopenia in multiple sclerosis: a review of the literature","volume":"219","author":"Russo","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.msard.2021.103384_bib0013","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00109-019-01761-5","article-title":"Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis","volume":"97","author":"Yadav","year":"2019","journal-title":"J. Mol. Med."},{"issue":"6","key":"10.1016\/j.msard.2021.103384_bib0014","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/ane.12882","article-title":"Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation","volume":"137","author":"Zecca","year":"2018","journal-title":"Acta Neurol. Scand."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821006519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821006519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T16:36:13Z","timestamp":1735576573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821006519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":14,"alternative-id":["S2211034821006519"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103384","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship between lymphopenia and disease activity in persons with multiple sclerosis treated with dimethyl fumarate","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103384","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103384"}}